TrialThe journal of headache and pain2021

Efficacy and safety of fremanezumab in patients with episodic and chronic migraine with documented inadequate response to 2 to 4 classes of migraine preventive medications over 6 months of treatment in the phase 3b FOCUS study.

Messoud Ashina et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.